ReviewBiomedicines2021
Immunomodulatory Role of Urolithin A on Metabolic Diseases.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Pomegranate (Nutrients · 2022Pooled it
- Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study.Journal of the International Society of Sports Nutrition · 2024Trial
- The effect of high-polyphenol Mediterranean diet on visceral adiposity: the DIRECT PLUS randomized controlled trial.BMC medicine · 2022Trial
- Review
- Functional Food-Derived Urolithins: Molecular Mechanisms, Health Effects, and Interactomics with Proteins and Extracellular Vesicles.Molecules (Basel, Switzerland) · 2026Review
- Urolithin A supplementation alleviates osteogenic disfunction and promotes bone fracture healing in inflammatory environments.Food & nutrition research · 2026Article
- Urolithin A: a multi-target therapeutic candidate derived from the gut microbiota for obesity and metabolic dysfunction.Frontiers in endocrinology · 2026Review
- Distinct classes of gut bacterial molybdenum-dependent enzymes produce urolithins.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Eicosapentaenoic Acid and Urolithin a Synergistically Mitigate Heat Stroke-Induced NLRP3 Inflammasome Activation in Microglial Cells.Nutrients · 2025Article
- Photoprotective, Antioxidant and Anti-Inflammatory Effects of AgedFood science & nutrition · 2025Article
- Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine.Nanotheranostics · 2025Review
- Advanced Spray-Dried Inhalable Microparticles/Nanoparticles of an Innovative Mitophagy Activator for Targeted Lung Delivery: Design, Comprehensive Characterization, Human Lung Cell Culture, and In Vitro Aerosol Dispersion Performance.ACS pharmacology & translational science · 2024Article
- Urolithin A exerts a protective effect on lipopolysaccharide-induced acute lung injury by regulating HMGB1-mediated MAPK and NF-κB signaling pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Urolithin A Hijacks ERK1/2-ULK1 Cascade to Improve CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Radiation-Induced Intestinal Injury: Injury Mechanism and Potential Treatment Strategies.Toxics · 2023Review
- Article
- Pharmacological Effects of Urolithin A and Its Role in Muscle Health and Performance: Current Knowledge and Prospects.Nutrients · 2023Review
- Cardiometabolic Risk: Characteristics of the Intestinal Microbiome and the Role of Polyphenols.International journal of molecular sciences · 2023Review
- Differential Role of Active Compounds in Mitophagy and Related Neurodegenerative Diseases.Toxins · 2023Review
- Preventive and Therapeutic Effects ofInternational journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Urolithin A (UroA) is a gut metabolite produced from ellagic acid-containing foods such as pomegranates, berries, and walnuts. UroA is of growing interest due to its therapeutic potential for various metabolic diseases based on immunomodulatory properties. Recent advances in UroA research suggest that UroA administration attenuates inflammation in various tissues, including the brain, adipose, heart, and liver tissues, leading to the potential delay or prevention of the onset of Alzheimer's disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. In this review, we focus on recent updates of the anti-inflammatory function of UroA and summarize the potential mechanisms by which UroA may help attenuate the onset of diseases in a tissue-specific manner. Therefore, this review aims to shed new insights into UroA as a potent anti-inflammatory molecule to prevent immunometabolic diseases, either by dietary intervention with ellagic acid-rich food or by UroA administration as a new pharmaceutical drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.